SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

About this update from Surenano Science Ltd

GlucaPharm is developing GEP44, a novel, patented peptide (similar in function to Ozempic®, Wegovy®, Mounjaro®, but with reduced risk of adverse events) discovered by researchers at Syracuse University. Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) ("SureNano" or the "Company") is pleased to announce that it has completed the acquisition of GlucaPharm Inc. ("GlucaPharm"), a next-generation glucagon-like peptide ("GLP") pharmaceutical company developing a patented therapeutic candidate designed to address obesity and metabolic disease with improved tolerability and delivery potential. The acquisition of GlucaPharm meaningfully strengthens SureNano's platform by accelerating its transition from an enabling-technology company into a near-term pharmaceutical value creator within one of the fastest-growing global drug markets. GlucaPharm's GEP44 developments directly align with SureNano's strategy of next-generation solutions that improve performance, tolerability, and delivery, mirroring SureNano's core value proposition: to improve how advanced therapeutics are delivered and experienced by patients. As previous announced, this Transaction has been structured as a share exchange where a total consideration paid by SureNano for this acquisition amounts to 8,100,999 common shares of the Company issued to GlucaPharm shareholders and warrants to purchase 5,000,000 common shares of the Company issued to the holder of GlucaPharm warrants, per the terms of the agreement (refer to press release dated November 19, 2025). The shares issued to GlucaPharm securityholders will be subject to the following hold period legend: the securities may not be sold, transferred, hypothecated or otherwise traded until the later of the approval by the Canadian Securities Exchange of a 2026 Annual Form 5A submitted by SureNano, and the release of the Company's 2026 annual audited financial statements. The Company is also pleased to announce the appointment of Dr. Nihar R. Pandey as a Director and Chief Scientific Officer. Dr. Pandey is an experienced biochemist and clinical researcher with over 25 years of expertise in drug discovery and development. He has developed several IP-protected drug formulations and led advancements in R&D and regulatory compl...

View stock analysis, news, and events for Surenano Science Ltd